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1. Introduction 
Human Cripto-1 is a member of the Epidermal Growth Factor-Cripto-FRL-1-cryptic (EGF-
CFC) family of peptides (Bianco et al., 2010; de Castro et al., 2010). During early vertebrate 
development, Cripto-1 functions as a co-receptor for transforming growth factor  (TGF-) 
ligands, such as Nodal and growth and differentiation factor-1 and -3 (GDF-1 and GDF-3), 
through an heteromeric complex composed of Activin type II and type I (ALK4) serine 
threonine kinase receptors in the plasma membrane. Genetic studies in zebrafish and mice 
have demonstrated that Cripto-1/Nodal signaling is essential for the formation of the 
primitive streak, patterning of the anterior/posterior (A/P) axis, specification of mesoderm 
and endoderm and establishment of left/right (L/R) asymmetry (Bianco et al., 2010; de 
Castro et al., 2010). In adult tissues, Cripto-1 is expressed at low levels in all stages of 
mammary gland development and its expression increases during pregnancy and lactation. 
Overexpression of Cripto-1 in mouse mammary epithelial cells leads to their transformation 
in vitro and can enhance migration, invasion, branching morphogenesis and epithelial to 
mesenchymal transition (EMT) (Bianco et al., 2010; de Castro et al., 2010). Furthermore, 
transgenic mouse studies have shown that overexpression of a human Cripto-1 transgene in 
the mouse mammary gland under the transcriptional control of the mouse mammary tumor 
virus (MMTV) promoter results in mammary hyperplasias and papillary adenocarcinomas 
(Wechselberger et al., 2005). Cripto-1 is also expressed at high levels in approximately 50-
80% of different types of human carcinomas, including breast, colon, pancreas, lung and 
ovary (Bianco et al., 2010; de Castro et al., 2010). Cripto-1 is therefore an example of an 
embryonic gene that plays an important role not only during embryogenesis, but is also 
implicated in malignant progression. Furthermore, Cripto-1 signaling might represent a 
common signaling pathway shared by embryonic stem cells and cancer cells. Recent studies 
have shown that Cripto-1 is an important component of critical core pathways that regulate 
stem cell self-renewal and differentiation (Hough et al., 2009). Chromatin 
immunoprecipitation  (ChiP) analysis has revealed the presence of Oct-4 and Nanog binding 
sites in the Cripto-1 promoter region, suggesting that Cripto-1 is a direct transcriptional 
target of Oct-4 and Nanog transcription factors (Loh et al., 2006). More importantly, several 
signaling pathways that are critical for early embryonic development and regulate stem cell 
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proliferation and differentiation have been shown to cross-talk with Cripto-1 (Bianco et al., 
2010). Examples of embryonic signaling pathways that interact with Cripto-1 are the Wnt-
/catenin, the Notch, hypoxia and TGF- signaling pathways.  Interestingly, Cripto-1 and 
other embryonic genes that regulate stem cell function are also overexpressed in human 
tumors, confirming this connection between stem cells and cancer. Recently, Cripto-1 has 
been shown to be highly expressed in a small subset of stem-like cells in human embryonal 
carcinoma cells, in human malignant melanomas and in androgen-responsive and refractory 
human prostate cancer cells (Cocciadiferro et al., 2009; Strizzi et al., 2008; Watanabe et al., 
2010). Therefore, Cripto-1 signaling pathway may represent an attractive target for 
treatment in cancer, because Cripto-1 targeting will eliminate not only differentiated cancer 
cells but also might target an undifferentiated subpopulation of tumor cells that exhibit 
stem-like characteristics, thereby leading to eradication of the tumor. In this review we will 
discuss the dual role of Cripto-1 as embryonic gene in the regulation of stem cell self-
renewal and differentiation and as oncogene with re-expression in human cancers.  
2. The EGF-CFC family  
Human Cripto-1 is a member of the EGF-CFC family of peptides identified only in 
vertebrates, and plays an important role in embryonic development and in tumor 
progression. The EGF-CFC family includes monkey Cripto-1, mouse Cripto-1 (Cr-1=cfc2), 
chicken Cripto-1, zebrafish one-eyed pinhead (oep), Xenopus XCR1/FRL-1, XCR2 and XCR3, 
mouse cryptic (Cfc1) and human Cryptic (CFC1) (Bianco et al., 2005b). Structurally, these 
proteins contain an NH2-terminal signal peptide, a modified EGF-like domain, a CFC 
cysteine-rich domain and a short hydrophobic COOH-terminus containing short sequences 
for glycosylphosphatidylinositol (GPI) cleavage and attachment (Figure 1).  
 
 
Fig. 1. Structure of the human Cripto-1 protein.  
Cripto-1 contains several glycosylation sites and the residue Threonin 88 within the EGF-
like domain modulates Cripto-1 ability to activate a Nodal-dependent signaling pathway. 
Cripto-1 can be cleaved from the cell membrane and can be released in the supernatant of 
cells by activity of the enzyme GPI-phospholipase D (GPI-PLD). EGF: epidermal growth 
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factor, CFC: Cripto-FRL-1-Cryptic, GPI: glycosylphosphatidylinositol, Ser: Serine, Asn: 
Asparagine, Thr: Threonine. 
GPI anchoring determines membrane localization of Cripto-1 within lipid rafts 
microdomains and is required for the paracrine activity of Cripto-1 as a Nodal co-receptor 
(Bianco et al., 2008; Watanabe et al., 2007b). Removal of the GPI anchor by GPI-PLD 
generates a soluble form of Cripto-1, which can therefore function both as a cell membrane 
anchored protein or as a soluble protein (Watanabe et al., 2007a; Watanabe et al., 2007b). In 
fact, soluble forms of Cripto-1 are biologically active in a number of different in vitro and in 
vivo assays (Minchiotti et al., 2001; Xu et al., 1999; Yan et al., 2002). Furthermore, Cripto-1 
protein has several glycosyl modification sites, including O-linked glycosylation at Ser40 
and Ser161 (-site for GPI-attachment), N-linked glycosylation at Asn79 and O-linked 
fucosylation at Thr88 (Figure 1) (Minchiotti et al., 2000; Schiffer et al., 2001; Shi et al., 2007; 
Watanabe et al., 2007a; Watanabe et al., 2007b). Among them, O-linked fucosylation of EGF-
CFC proteins is required for their ability to function as co-receptors for the TGF--related 
protein Nodal (Schiffer et al., 2001). However, Cripto-1 O-fucosylation mutants are fully 
functional with regard to activation of Nodal independent signaling pathways (Bianco et al., 
2008). Another study has demonstrated that is the Thr88 residue and not fucosylation of this 
residue that is necessary for Cripto-1 to function as a Nodal co-receptor (Schiffer et al., 2001; 
Shi et al., 2007). 
3. Cripto-1 during embryonic development  
In the embryonic development EGF-CFC proteins function as co-receptors for the TGF- 
ligands Nodal, GDF-1 and GDF-3 (Bianco et al., 2010; de Castro et al., 2010 as cited in Yeo et 
al. 2001; Andersson at al. 2007). Genetic studies in zebrafish and mice have defined an 
essential role for Nodal that functions through oep/Cripto-1 in the formation of the 
primitive streak, patterning of the A/P axis, and specification of mesoderm and endoderm 
(mesoendoderm) (Bianco et al., 2010; de Castro et al., 2010 as cited in Chu et al. 2005). In 
later stages of embryonic development the EGF-CFC ortholog of Cripto-1, Cryptic, regulates 
the establishment of L/R axis, allowing asymmetric development of visceral organs (Bianco 
et al., 2010 as cited in Yan et al., 1999). Biochemical studies have demonstrated that EGF-
CFC proteins bind directly to Nodal, GDF-1 or GDF-3 and the Activin type I receptor ALK4 
(ActRIB), recruiting the Activin type II receptor and inducing activation and 
phosphorylation of Smad-2/Smad-3 signaling pathway (Bianco et al., 2010) (Figure 2). 
However, Cripto-1 can also regulate A/P axis specification independently of Nodal 
signaling (D'Andrea et al., 2008). In fact, Cripto-1F78A/F78A mouse embryos carrying the 
amino acid substitution F78A are unable to activate a Nodal signaling pathway but clearly 
establish an A/P axis and initiate germ layer formation and gastrulation movements 
(D'Andrea et al., 2008). During early mouse embryogenesis, Cripto-1 cannot be detected 
until prior to the gastrulation stage in the inner cell mass and in extra-embryonic 
trophoblast cells at day 4 of development. Increase in Cripto-1 expression is observed on 
day 6.5 of embryonic development when Cripto-1 is found in the primitive streak within 
epiblast cells undergoing EMT, which eventually give rise to mesoderm and endoderm 
(Bianco et al., 2010; de Castro et al., 2010). Cripto-1 is also detected in the ectoplacental cone 
at this stage. Cripto-1 expression then decreases on day 7 when it is detected mostly in the 
truncus arterious of the developing heart. 
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Fig. 2. Cripto-1/Nodal dependent signaling pathway. 
Cripto-1 is a co-receptor for Nodal, GDF-1 and GDF-3, allowing them to interact with ALK4 
(ActRIB). The Cripto-1/Nodal/ALK4/ActRII receptor complex triggers activation and 
phosphorylation of Smad-2 and Smad-3. Phosphorylated Smad-2 and Smad-3 form a 
complex with Smad-4 and they translocate into the nucleus. In the nucleus, Smad-2/-3/-4 
complex interacts with CREB binding protein (CBP)/p300 and activates transcription of 
specific target genes. The heat shock protein GRP78 can also enhance Cripto-1/Nodal-
dependent signaling pathway, as discussed later in the text. GDF-1/-3: growth and 
differentiation factor-1/3, GRP78: glucose-regulated protein 78. 
With the exception of the developing heart, little if any expression of Cripto-1 can be 
detected in the embryo after day 8 (Bianco et al., 2010; de Castro et al., 2010 as cited in Dono 
et al., 1993; Minchiotti et al., 2000). Disruption of Cripto-1 in Cripto-1 -/- embryos is 
embryonically lethal and results in the formation of embryos that possess a head without a 
trunk, demonstrating that there is a severe deficiency in embryonic mesoderm and 
endoderm without a loss of anterior neuroectoderm formation (de Castro et al., 2010 as cited 
in Ding et al. 1998). Initiation of the primitive heart tube in Cripto-1 -/- mice is severely 
inhibited due to failure in the development of functional beating cardiomyocytes, as 
demonstrated by the absence of expression of terminal myocardial differentiation genes (de 
Castro et al., 2010 as cited in Xu et al., 1998). Cripto-1 -/- embryonic bodies (EB) derived from 
Cripto-1 -/- embryonic stem (ES) cells fail to form beating cardiomyocytes, while they 
differentiate into neuronal cells. Addition of a Cripto-1 recombinant protein to Cripto-1 -/- 
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EBs during early time points (0–2 days) of differentiation is able to rescue cardiomyocyte 
differentiation. However, addition of Cripto-1 recombinant protein during later stages of 
differentiation fails to rescue cardiamyocyte differentiation, suggesting that Cripto-1 ability 
to promote cardiac differentiation of EB is restricted to an early window of this 
differentiation program (Minchiotti, 2005, as cited in Parisi et al., 2003). Interestingly, a 
microarray study revealed that Cripto-1 -/- ES cells had a reduced mRNA expression of the 
G protein coupled receptor APJ (also known as angiotensin type I-like receptor) and its 
ligand Apelin, as compared to control wild type ES cells. Gain of function experiments 
showed that APJ redirects the neural fate of Cripto-1 -/- ES cells and restores the cardiogenic 
program. Furthermore, comparison of Cripto-1, APJ and Apelin expression profile in mouse 
embryo by in situ hybridization revealed that expression of Apelin and APJ correlates with 
Cripto-1 expression. In fact, Apelin mRNA was clearly expressed in the developing 
primitive streak, whereas APJ was expressed in the primitive streak and adjacent 
mesoderm, resembling Cripto-1 expression pattern (D'Aniello et al., 2009). Therefore, APJ 
and Apelin are downstream targets of Cripto-1 signaling pathway and together with Cripto-
1 they drive ES cells toward a cardiac lineage. 
3.1 Cripto-1 in embryonic stem cells 
Stem cells have the capacity to divide for an undetermined period of time and a potential to 
develop into many different cell types throughout early life and growth. Stem cells are 
distinguished from other cell types by two important characteristics. First, they possess the 
capability to differentiate into mature cells of any particular tissue (pluripotency). Second, 
they can undergo through numerous cell cycle divisions while maintaining their 
undifferentiated state (self-renewal). ES cells can be isolated from a 3- to 5-day-old embryo, 
called blastocyst, and have the potential to give rise to all specialized tissues and organs of a 
mature organism. Adult stem cells are found in various adult tissues, and function as a 
reservoir for cells that are lost during injury or disease (Bendall et al., 2008). Mouse 
embryonic stem cells (mES) or human embryonic stem cells (hES) have been very useful in 
the field of stem cell research. Comparison of gene expression profiles across species has 
shown that mouse and human ES cells share common highly conserved signaling pathways 
that regulate self-renewal and pluripotency, including the Cripto-1/Nodal signaling 
pathway. For example, in addition to Cripto-1, genes such as Oct-4, Lefty, Nodal, Sox-2, Utf-
1 (undifferentiated embryonic cell transcription factor-1) and Tert (telomerase reverse 
transcriptase) are highly enriched in both mouse and human ES cells (Wei et al., 2005). 
Additionally, Cripto-1 has been identified as a pluripotency marker also in primate ES cells 
together with Oct-4, Nanog, Sox-2, Tert, LeftyA, and Rex-1 (Chang et al., 2010). In 2007 a 
comparative study of a large and diverse set of hES cell lines assessed the expression pattern 
of commonly used stem cell markers. All the hES cells analyzed exhibited similar expression 
profile for several stem cell markers, including the glycolipid stage specific embryonic 
antigens SSEA3 and SSEA4, the keratan sulfate antigens TRA-1-60, TRA-1-81, and the 
developmentally regulated genes including Nanog, Oct-4, Dnmt3b, Gabrb3, GDF-3 and 
Cripto-1 (Adewumi et al., 2007; Bianco et al., 2010; de Castro et al., 2010). Finally, Cripto-1 
has been reported as a direct target gene of stem cell transcription factors (Bianco et al., 2010; 
de Castro et al., 2010; Hough et al., 2009). For instance, using the ChIP paired-end ditags 
method, Loh and collaborators mapped the binding sites of the transcription factors Oct-4 
and Nanog in the mouse ES cell genome. Cripto-1 promoter was found to include Oct-4 and 
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Nanog binding sites, suggesting that key modulators of stem cell self-renewal and 
pluripotentiality directly regulate Cripto-1 expression in ES cells (Bianco et al., 2010; de 
Castro et al., 2010; Loh et al., 2006). 
3.1.1 Cross-talk of Cripto-1 with stem cell signature pathways 
Several signaling pathways regulate in a coordinate fashion early embryonic development 
and stem cell proliferation, maintenance and differentiation. Some of these signaling 
cascades have been shown to cross-talk with Cripto-1 signaling, suggesting a pivotal role 
played by Cripto-1 in stem cell self-renewal and maintenance. Among these signaling 
pathways are genes in the Wnt/-catenin signaling pathway, TGF- family members, the 
Notch pathway, and hypoxia inducible factor-1 alpha (HIF-1) (Bianco et al., 2010; de Castro 
et al., 2010). A schematic diagram of the cross-talk of Cripto-1/Nodal signaling with other 
stem cell signature signaling pathways is shown in figure 3. 
 
 
Fig. 3. Interplay of Cripto-1/Nodal signaling with other embryonic stem cell signaling 
pathways. 
Cripto-1 signaling is a downstream target of Oct-4, Nanog, Wnt/-catenin, Notch and 
Hypoxia/HIF-1 pathways. Cripto-1 also mediates signaling of TGF- family members and 
enhances Notch signaling by facilitation of Notch receptor maturation. TGF-: transforming 
growth factor-, HIF-1: hypoxia inducible factor-1, GDF-1/-3: growth and differentiation 
factor-1/-3, BMP-4: bone morphogenetic protein-4, ES cells: embryonic stem cells, mES cells: 
mouse embryonic stem cells. 
Activation of the canonical Wnt/-catenin pathway has been reported to sustain the 
undifferentiated state of ES cells by triggering transcription of genes that regulate ES cell 
pluripotency and self-renewal, such as Oct-4, Nanog, Sox-2 and Cripto-1. For instance, 
Cripto-1 has been identified as a direct target gene in the canonical Wnt/-catenin signaling 
pathway during embryonic development and in colon carcinoma cell lines and tissues 
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(Morkel et al., 2003). Remarkably, in -catenin -/- or Wnt3 -/- mutant mouse embryos, Cripto-
1 expression was found to be dramatically downregulated, suggesting that the Wnt/-
catenin signaling pathway is a positive regulator of Cripto-1 expression during embryonic 
development (Bianco et al., 2010). In addition, in Xenopus, the Cripto-1 ortholog XCR1/FRL-
1 functions as a co-receptor for Wnt11 and together with frizzled receptor 7 and Glypican-4 
mediates stabilization and activation of -catenin (Bianco et al., 2010). Several studies have 
clearly implicated Wnt/-catenin signaling pathway in initiation and maintenance of 
carcinomas of the skin, intestine, liver, and brain (Bianco et al., 2010; de Castro et al., 2010). 
Hence, the interaction between the Wnt/-catenin and Cripto-1 signaling pathways might 
be significant also in cancer initiation and progression. Activation of TGF-/Activin/Nodal 
signaling has also been reported to be required for the maintenance of undifferentiated state 
in human ES cells (James et al., 2005; Vallier et al., 2009). Some TGF- family members, 
including Nodal, GDF-1 and GDF-3, require Cripto-1 for signaling and they are critical for 
ES cell maintenance and self-renewal (Bianco et al., 2010). Furthermore, Activin, TGF- and 
bone morphogenetic protein (BMP)-4 can directly regulate Cripto-1 expression by binding to 
smad binding elements (SBE) within the Cripto-1 promoter in human embryonal carcinoma 
cells and in human colon cancer cells (Mancino et al., 2008). GDF-3 and Cripto-1 have also 
been identified as ES cell markers that are enriched in a population of ES cells which are 
uncommitted and have high self-renewal capacity (Hough et al., 2009). Finally, 
Activin/TGF- signaling activity is required for Nanog expression in epiblast cells, 
suggesting a key role played by TGF- family members in maintaining ES pluripotency and 
self-renewal (Shin et al., 2011; Wang et al., 2009). The Notch pathway is a key regulator of 
many developmental processes during fetal and adult differentiation. Studies have reported 
that inappropriate activation of Notch signaling cascade contributes to tumorigenesis 
(Wilson & Radtke, 2006; Wang et al., 2009). Interaction between Notch and Cripto-1/Nodal 
signaling pathways has also been described. Analysis of the transcriptional regulatory 
regions within the mouse Nodal promoter has identified the presence of CBF1 binding 
elements, suggesting a direct regulation of Nodal expression by Notch signaling (Bianco et 
al., 2010; as cited in Raya et al., 2003; Krebs et al 2003). In this regard, mouse embryo double 
mutants for Notch1 and Notch2 exhibit multiple defects in L/R asymmetry, which is 
regulated by Nodal. Moreover, a new insight into Notch and Cripto-1/Nodal signaling 
pathways has been reported. Watanabe and colleagues (2009) using a yeast two-hybrid 
system screened a mouse embryo or human colon cDNA prey library for potential Cripto-1 
binding partners. Six candidate genes were isolated, including the mouse Notch3. By 
coimmunoprecipitation analysis Cripto-1 was found to directly bind to all four mammalian 
Notch receptors. Surprisingly, binding of Cripto-1 to Notch1 occurred mainly inside the 
cells in the endoplasmic reticulum/Golgi complex, where Cripto-1 enhanced cleavage of the 
Notch1 extracellular domain through a furin-like convertase. Enhanced cleavage of Notch1 
receptor by Cripto-1 potentiates Notch signaling as demonstrated by enhanced ligand-
induced activation of Notch signaling in Chinese hamster ovary cells expressing a CBF1-
dependent Notch reporter assay (Watanabe et al., 2009). Hypoxia is an important regulator 
of stem cell proliferation and differentiation (Yeung et al., 2011). In fact, tissue stem cells 
reside within niches that are naturally hypoxic and low oxygen levels prevent their 
differentiation toward specific fates. Moreover, HIF-2 can directly regulate Oct-4 
expression in ES cells by binding to hypoxia-responsive elements (HREs) within the 
promoter of mouse Oct-4. HIF-1 interacts with Notch signaling by binding to Notch 
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intracellular domain and enhancing transcription of Notch downstream target genes Hes-1 
and Hey-2. HIF-1, in addition to regulating Notch1 signaling, can also regulate Cripto-1 
expression by binding to HREs within the promoter region of mouse and human Cripto-1 
gene in mouse ES cells and in human embryonal carcinoma cells (Bianco et al., 2009). In 
addition, hypoxic conditions enhanced differentiation of mES cells into beating 
cardiomyocytes when compared with mES cells grown under normoxic conditions. 
However, expression of Cripto-1 in mES was critical, because hypoxia was unable to induce 
differentiation of mES cells into cardiomyocytes in the absence of Cripto-1 expression.  
4. Cripto-1 in cancer 
Similarities between embryonic development and cellular transformation during 
oncogenesis have led to the identification of common signaling pathways, suggesting that 
reactivation of developmental signaling pathways might drive cell transformation and 
tumor progression in adult tissues (Bianco et al., 2010). Cripto-1 is a typical example of an 
embryonic gene that is re-expressed in human tumors, promoting cellular proliferation, 
migration, and tumor angiogenesis (Figure 4).  
 
 
Fig. 4. Expression of Cripto-1 during embryogenesis and tumorigenesis. 
Cripto-1 is highly expressed in undifferentiated embryonic stem cells and germ cells. Cripto-
1 is important for mesoendoderm differentiation of ES cells and its expression is lost upon 
differentiation of ES cells toward the three germ cell layers. In the adult, Cripto-1 is re-
expressed by tumor cells. Green color: no Cripto-1 expression, red color: Cripto-1 
expression. ICM: Inner cell mass, ES: embryonic stem cells. 
4.1 Cripto-1 oncogenic activities in vitro and in vivo 
The first evidence of Cripto-1 oncogenic activity derives from studies demonstrating that 
Cripto-1 overexpression can induce in vitro transformation of a variety of cells, including 
NIH-3T3 fibroblasts and NOG-8 or CID9 mouse mammary epithelial cells (Ciardiello et al., 
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1991; Ciccodicola et al., 1989; Niemeyer et al., 1998). Furthermore, Cripto-1 can enhance 
migration and invasion of a variety of normal mammary epithelial cells and human breast 
and cervical carcinoma cells, suggesting the involvement of Cripto-1 in tumor progression 
(Ebert et al., 2000; Normanno et al., 2004a; Wechselberger et al., 2001). Cripto-1 can also 
function as a potent angiogenic protein both in vitro and in vivo, enhancing the proliferation, 
migration and invasion of human umbilical vascular endothelial cells and stimulating their 
differentiation into vascular-like structures in matrigel. Likewise, overexpression of Cripto-1 
promotes in vivo neovascularization of MCF-7 xenografts, supporting a role for Cripto-1 in 
modulating tumor angiogenesis (Bianco et al., 2005a). Since HIF-1 can enhance Cripto-1 
expression by directly binding to the Cripto-1 promoter, it is possible that the hypoxic 
microenvironment within the growing tumor might enhance Cripto-1 expression, which in 
turn induces new vessel formation to sustain tumor growth (Bianco et al., 2009). Cripto-1 
has also been directly implicated in mouse mammary tumor development (Sun et al., 2005; 
Wechselberger et al., 2005), as demonstrated by transgenic mouse models overexpressing 
the human Cripto-1 transgene in mouse mammary glands under the control of the MMTV 
or whey acidic protein (WAP) promoter (Sun et al., 2005; Wechselberger et al., 2005). The 
majority of nulliparous MMTV-Cripto-1 transgenic mice exhibited enhanced ductal 
branching, intraductal hyperplasias and hyperplastic alveolar nodules, and about 30-40% of 
aged multiparous female mice developed multifocal hyperplasias and papillary 
adenocarcinomas (Wechselberger et al., 2005). Interestingly, under a 2 years observation 
period, approximately 20% of female nulliparous or multiparous MMTV-Cripto-1 
transgenic mice developed uterine leiomyosarcomas as compared to control mice. High 
levels of Cripto-1 transgene, phosphorylated forms of c-Src, AKT, glycogen synthase kinase-
3 (GSK-3) and dephosphorylated active--catenin were detected in the uterine tumors 
collected from MMTV-Cripto-1 transgenic mice (Strizzi et al., 2007), suggesting a role for 
Cripto-1 during uterine tumorigenesis either by activation of c-Src and Akt and/or via 
cross-talk with the canonical Wnt/-catenin signaling pathway. Unlike the MMTV 
promoter, the WAP promoter is maximally active during mid-pregnancy and lactation. 
Approximately 50% of old nulliparous WAP-Cripto-1 mice developed multifocal intraductal 
hyperplasias, and more than 50% of multiparous WAP-Cripto-1 female mice developed 
multifocal mammary tumors of mixed histological subtypes (Sun et al., 2005). Histological 
analysis of the WAP-Cripto-1 mammary tumors revealed the presence of tumors containing 
glandular, papillary and undifferentiated carcinoma, as well as myoepithelioma and adeno-
squamous carcinoma. Mammary tumors with mixed histology have also been described in 
MMTV-Wnt-1 transgenic mice, which have alterations in the canonical Wnt/-catenin 
pathway. Interestingly, hyperactivation of a canonical Wnt/-catenin pathway was detected 
in WAP-Cripto-1 mammary tumors, suggesting that the canonical Wnt/-catenin pathway 
together with Cripto-1 might play an important role during mammary transformation in 
vivo (Miyoshi et al., 2002a; Miyoshi et al., 2002b; Sun et al., 2005). Finally, several studies 
have demonstrated that Cripto-1, in addition to function as an oncogene in vitro and in 
animal models, is overexpressed at the mRNA and protein level in a wide variety of human 
tumors, including colorectal, breast, gastric, pancreatic, ovarian, endometrium, nasopharynx 
and lung carcinomas, while very little or no expression is detected in normal adult tissues. 
Therefore, the selective expression of Cripto-1 in cancer cells suggests that it represents a 
promising target in cancer therapy. For an extensive review on Cripto-1 expression in 
human tumors see de Castro et al., 2010. 
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4.1.1 Intracellular signaling pathways activated by Cripto-1 during oncogenic 
transformation 
While Cripto-1 functions mostly in a Nodal-dependent manner during embryogenesis, 
several studies have demonstrated that Cripto-1 induces cellular proliferation, motility, 
survival and EMT in a Nodal-independent fashion. Following binding to the GPI-linked 
heparan sulphate proteoglycan Glypican-1, Cripto-1 induces activation and phosphorylation 
of the cytoplasmic tyrosine kinase c-Src, which in turn activates mitogen-activated protein 
kinase (MAPK)/Phosphatydil inositol 3’ kinase (PI3K)/Akt signaling pathways (Figure 5) 
(Bianco et al., 2005b).  
 
 
Fig. 5. Nodal-independent Cripto-1 signaling pathway. 
Cripto-1 upon binding to Glypican-1 activates MAPK and Akt signaling pathways during 
tumor progression, enhancing cell proliferation and survival. MAPK and PI3K/Akt pathways 
can also inhibit GSK-3 leading to activation and stabilization of -catenin. GRP78 can also 
enhance Cripto-1 activation of the MAPK/Akt signaling pathways. GRP78: glucose-regulated 
protein 78, MAPK: mitogen-activated protein kinase, PI3K: phosphatydil inositol 3’ kinase, 
GSK3 : glycogen synthase kinase 3, TCF/LEF: T-cell factor/lymphoid enhancer factor, RSK: 
Ribosomal s6 kinase, STAT: signal transducers and activators of transcription. 
Activation of the MAPK and PI3K/Akt signaling pathways by Cripto-1 is independent of 
Nodal and ALK4, since Cripto-1 can enhance phosphorylation of MAPK and Akt in cells 
lacking ALK4 and/or Nodal expression (Bianco et al., 2002). Furthermore, the tyrosine 
kinase c-Src is required by Cripto-1 to induce in vitro transformation of mouse mammary 
epithelial cells, indicating that inappropriate activation of c-Src by Cripto-1 in a Nodal- and 
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ALK4-independent manner might play a key role in Cripto-1 tumorigenic activity (Bianco et 
al., 2003). The interaction between Cripto-1 and Gypican-1 occurs within lipid raft 
microdomains, regions of the cell membrane that are enriched in GPI-linked proteins 
(Bianco et al., 2003). Cripto-1 mitogenic signaling is also dependent upon binding to GRP78, 
an endoplasmic reticulum (ER) heat shock chaperone protein that is expressed on the cell 
surface of tumor cells (Shani et al., 2008). Indeed, disruption of the Cripto-1/GRP78 complex 
at the cell membrane interferes with Cripto-1 oncogenic activity in vitro, preventing Cripto-1 
activation of MAPK/Akt signaling pathway (Figure 5). Interestingly, unlike Glypican-1, 
GRP78 is also important for Nodal-dependent Cripto-1 signaling, enhancing activation of 
the Smad-2/Smad-3 signaling pathway (Kelber et al., 2009). Furthermore, GRP78 enhanced 
Cripto-1-dependent activation of the c-Src/MAPK/Akt signaling pathways, increased 
cellular proliferation and reduced cell adhesion, as evidenced by a decrease in E-cadherin 
expression in breast cancer cells (Kelber et al., 2009). 
5. Cripto-1 and Cancer Stem Cells 
Cancer stem cells (CSCs), also known as tumor initiating cells, share characteristics 
associated with embryonic stem cells, specifically the ability to give rise to all cell types 
within a particular tumor tissue. CSCs were first identified in the hematopoietic system and 
later they have also been reported in solid cancers, including cancers of the breast, lung, 
prostate, colon, brain, head and neck, and pancreas (Bianco et al., 2010; de Castro et al., 
2010). CSCs represent a distinct population of cancer cells with innate chemo- and radio-
resistance and therefore are responsible of tumor relapse (Bianco et al., 2010; de Castro et al., 
2010 as cited in Huntly and Gilliland 2010). Moreover, CSCs are capable to self-renew and 
regenerate the original phenotype of the tumor when implanted into immunodeficient mice 
(Visvader & Lindeman, 2008). Similarities between embryonic development and cell 
transformation during oncogenesis have led to the identification of common contributing 
pathways, suggesting that reactivation of developmental signaling pathways might drive 
cell transformation and tumor progression in adult tissues (Bianco et al., 2010). Cripto-1 is a 
typical example of a common gene shared by embryonic cells and cancer cells contributing 
to early embryogenesis and cancer progression. More importantly, Cripto-1 is enriched in a 
subpopulation of cancer cells with stem-like characteristics. For instance, Watanabe and 
collaborators (2010) described a heterogeneous Cripto-1 expression pattern in human 
embryonal carcinoma (EC) with segregation of these cells into two distinct populations 
portraying high and low Cripto-1 expression. EC cells are pluripotent stem cells derived 
from germ cell teratocarcinomas and they represent the malignant counterparts of human 
ES cells. Interestingly, these two subpopulations showed different gene expression profiles 
and different in vitro and in vivo tumorigenic capability. The Cripto-1 high subpopulation of 
EC cells formed tumor spheres in a serum-free suspension culture with an efficiency 
significantly higher than the Cripto-1 low expressing EC cells. Furthermore, the Cripto-1 
high expressing EC cells were able to generate tumors larger in size and with a shorter 
tumor latency period compared with tumors derived from Cripto-1 low expressing EC cells 
when injected subcutaneously into nude mice. Finally, regulators of pluripotent ES cells, 
such as Activin/Nodal signaling and the transcription factors Nanog and Oct-4, positively 
regulated Cripto-1 expression in Cripto-1 high expressing EC cells, suggesting the existence 
of a core transcriptional regulatory network of pluripotent stem cell transcription factors 
that cross-regulate each other expression (Loh et al., 2006). However, Cripto-1 expression is 
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dispensable for pluripotent stem cell gene expression in EC cells, since siRNA-mediated 
knockdown of Cripto-1 has no effect on the expression of ES-related genes including Oct-4, 
Nanog, Sox-2 and Lefty. In another study, Cripto-1 has been exploited as a potential 
melanoma stem cells candidate marker in human malignant melanomas (Strizzi et al., 2008). 
Strizzi and colleagues, by FACS cell sorting based on Cripto-1 expression, isolated from a 
human melanoma cell line a subpopulation with stem-like characteristics. The Cripto-1 
positive subpopulation of melanoma cells represented a relatively smaller size population 
with a more spindle-shaped morphology, and showed increased expression of the stem cell 
associated transcription factors, Oct-4 and Nanog, as compared to the parental melanoma 
cells. Finally, Cripto-1 and the stem cell markers Oct-4 and SUZ-12 were identified in a small 
subpopulation of stem-like cells in hormone-responsive and nonresponsive prostate tumor 
cell (Cocciadiferro et al., 2009). Altogether, these findings suggest that Cripto-1 might be 
useful in the identification of a subpopulation of cancer cells with stem like behavior that are 
resistant to conventional therapy and are therefore a major obstacle in the clinical treatment 
of cancer patients.  
5.1 Cancer stem cells and EMT 
During embryogenesis, tumor progression and metastasis, epithelial cells undergo dramatic 
morphological changes, acquiring mesenchymal properties in a process known as EMT. In 
the embryo, Cripto-1 is detected at high levels in epiblast cells undergoing EMT, which 
migrate through the primitive streak, eventually giving rise to the mesoderm and endoderm 
(Bianco et al., 2005b; Strizzi et al., 2005). In the tumor, the expression of EMT regulators at 
the tumor periphery is critical for tumor cells to acquire a mesenchymal phenotype that 
allow them to locally invade and escape from the primary tumor site, leading to the 
establishment of metastatic lesions (Micalizzi et al., 2010a). Cripto-1 is involved in tumor 
epithelial cells plasticity and may be an important EMT regulator together with Snail, Slug, 
Twist, and Six1 (Micalizzi et al., 2010b). It has been shown that mammary gland 
hyperplasias and tumors derived from MMTV-Cripto-1 transgenic mice express molecular 
markers and signaling molecules characteristics of EMT, suggesting that Cripto-1 might 
play an important role in facilitating migration and invasion of tumor cells (Strizzi et al., 
2004). These findings might be significant since emerging evidence has suggested a link 
between stem cells and EMT (Hollier et al., 2009). In fact, EMT induction in immortalized 
human mammary epithelial cells resulted in the expression of stem cell markers and 
increased ability to form mammospheres in vitro, suggesting an important role for EMT in 
generating cancer stem-like cells in human breast tumors (Mani et al., 2008). Since Cripto-1 
has been found to promote EMT in mouse mammary epithelial cells and mouse mammary 
tumors, contributing to a more aggressive mesenchymal phenotype, it is possible that 
Cripto-1 might support self-renewal, invasiveness and metastatic abilities of breast cancer 
stem-like cells through induction of an EMT program (Strizzi et al., 2004).  
6. Cripto-1 as target for cancer therapy 
High expression of Cripto-1 in human carcinomas and its enrichment in a stem-like cancer 
cell subpopulation strongly support Cripto-1 as a promising candidate for therapeutic 
intervention in cancer. Two different therapeutic approaches have been successfully used to 
impair Cripto-1 activity in cancer cells, including anti-Cripto-1 antisense (AS) 
oligonucleotides and neutralizing monoclonal antibodies (Adkins et al., 2003; Hu et al., 2007; 
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Normanno et al., 1996; Normanno et al., 2004b). For instance, a significant growth inhibition 
in vitro has been observed in ovarian, breast and colon cancer cells treated with anti-Cripto-1 
AS oligonucleotides. A synergistic growth inhibitory effect was detected when anti-Cripto-1 
AS oligonucleotides were combined together with oligonucleotides against TGF- and 
amphiregulin (AREG), indicating that a variety of growth factors might cooperate in 
stimulating cancer cell proliferation (Casamassimi et al., 2000; De Luca et al., 2000; De Luca 
et al., 1999; Normanno et al., 2004b). Additionally, combination of anti-Cripto-1 AS 
oligonucleotides with anti-TGF- and anti-AREG AS oligonucleotides was more effective in 
vivo as compared to single AS oligonucleotide administration, inhibiting the growth of colon 
cancer tumor xenografts in nude mice in a dose dependent manner (De Luca et al. 2000). 
Neutralizing antibodies that bind Cripto-1 have also been generated (Adkins et al., 2003; Hu 
& Xing, 2005). In particular, Adkins and colleagues of Biogen-Idec have generated a panel of 
monoclonal antibodies (mAbs) directed against a human recombinant Cripto-1 protein 
expressed as a human IgG1 Fc fusion protein (Adkins et al. 2003). The mAbs are capable to 
recognize different domains of the Cripto-1 protein, detecting its expression in human breast 
and colon tumor tissue samples and in human cancer cell lines. Among these anti-Cripto-1 
mAbs, anti-CFC mAbs showed blocking activities in vitro and in vivo by interfering with the 
binding of Cripto-1 with ALK4 through the CFC domain. The anti-CFC blocking antibodies 
also blocked the interaction of Cripto-1 with Activin B (Adkins et al. 2003), restoring the 
growth inhibitory function of Activin B in tumor cells. Recently, among these anti-Cripto-1 
mAbs, an N-terminal anti-Cripto-1 antibody has been selected to target Cripto-1 in human 
tumors, due to the higher binding affinity and range of reactivity of this antibody with 
tumor-derived Cripto-1 (Kelly et al., 2011). A humanized form of the anti-Cripto-1 N-
terminal monoclonal antibody-conjugated to a DM4 toxin is currently been evaluated in 
phase I clinical trials for treatment of patients with refractory or relapsed Cripto-1 positive 
solid tumors (A phase I study of BIIB015 in relapsed/refractory solid tumors, protocol ID 
207ST101/NCT00674947) (Bianco & Salomon, 2010). BIIB015 showed specificity for Cripto-1 
in vitro and in vivo with a clinical response ranging between 50% of tumor inhibition to 
complete tumor regression in xenograft mouse models inoculated with lung (Calu-6), colon 
(CT-3), testicular (NCCIT) or breast (MDA-MB-231) human tumor cell lines (Kelly et al., 
2011). In addition to mouse monoclonal antibodies against Cripto-1, anti-Cripto-1 rat 
monoclonal antibodies have also been generated. Rat anti-Cripto-1 monoclonal antibodies 
inhibited tumor cell growth and increased sensitivity of LS174T human colon cancer cells 
and MCF-7 human breast cancer cells to the cytotoxic effects of chemotherapeutic agents 
such as cisplatin, 5-Fluorouracil, carboplatin and epirubicin (Xing et al., 2004). Furthermore, 
a C13 rat monoclonal antibody inhibited cancer cell growth in vivo in LS174T tumor 
xenografts in SCID mice, inducing up to 80% growth inhibition of established tumors as 
compared to an untreated control groups. Interestingly, C4 and C13 rat monoclonal 
antibodies were also highly effective in reducing tumor growth of a human leukemia 
multidrug resistant (MDR) cell line (CEM/A7R) both in vitro and in vivo in an established 
xenograft tumor model (Hu et al., 2007).  
6.1 Cripto-1 as a target for therapy in neurodegenerative and muscle degenerative 
diseases 
Recent findings have demonstrated that Cripto-1 is a key player in the signaling pathway 
controlling neural induction in ES cells. Parisi and collaborators showed that Cripto-1 
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negatively regulated neuronal differentiation of ES cells (Parisi et al., 2003). Furthermore, 
disruption of Cripto-1 expression in mouse ES cells enhances neurogenesis and midbrain 
dopaminergic differentiation in vitro (Parish et al., 2005; Sonntag et al., 2005). These results 
suggest that blocking Cripto-1 expression and activity may provide a novel insight into the 
treatment of neurodegenerative diseases. Parkinson’s disease is a progressive 
neurodegenerative disorder characterized by degeneration of dopaminergic neurons of the 
substantia nigra. Therefore methods that channel undifferentiated ES cells into 
dopaminergic neurons are under extensive evaluation, aiming to improve the safety of ES 
cells grafting that often results in uncontrolled proliferation and teratoma formation (Parish 
& Arenas, 2007). In a rat animal model of Parkinson’s disease, mouse ES cells that are null 
for Cripto-1 expression (Cripto-1-/- ES cells), when grafted at low density into rats, 
differentiated into neuronal cells in the brain and were able to restore normal behavior 
without producing teratomas (Parish et al., 2005). Recently, a tetrameric tripeptide, which 
prevents Cripto-1/ALK4 interaction and interferes with Cripto-1 signaling was identified 
(Lonardo et al., 2010). The Cripto-1 blocking peptide was able to induce formation of 
neuroectoderm and increased midbrain dopaminergic neuron differentiation of mouse ES 
cells in vitro and in vivo (Lonardo et al., 2010). Moreover, mouse ES cells treated with Cripto-
1 blocking peptide enhanced functional recovery and reduced tumor formation in 
Parkinsonian rats (Lonardo et al., 2010). Overexpression of Cripto-1 has also been observed 
in the cerebral cortical tissues of macaques that had been infected with a chimeric simian 
human immunodeficiency virus (SHIV) by cDNA array analysis (Stephens et al., 2006). 
SHIV enters the central nervous system (CNS) early after inoculation and cause encephalitis, 
characterized by transient meningitis and astrocytosis. Immunohistochemical analysis and 
RT-PCR confirmed widespread expression of Cripto-1 in the brains of SHIV-infected 
macaques. Although the functions of Cripto-1 in the neurons of the adult brain and the 
overexpression in the brains of SHIV-infected macaques are unclear, Cripto-1 may play a 
neuroinflammatory role and targeting Cripto-1 with various approaches, such as the 
tetrameric tripeptide described by Lonardo and colleagues, might inhibit progression of 
neurodegenerative disease in mammals. Cripto-1 may also be involved in degenerative 
muscle diseases, such as muscular dystrophy and spinal muscular atrophy. These diseases 
are characterized by skeletal muscle loss and few therapeutic approaches are available to 
restore the function of the lost muscle tissue (Tedesco et al., 2010). Cripto-1 is highly 
expressed in myoblast cells of regenerative muscles, whereas no expression of Cripto-1 is 
detected in normal muscle fibers. Furthermore, Cripto-1 induced a dose-dependent increase 
in proliferation and migration of myogenic precursor cells in vitro and enhanced skeletal 
muscle regeneration and angiogenesis after injury in vivo (Bianco & Salomon, 2010). These 
studies clearly suggest an involvement of Cripto-1 in neurodegenerative and muscle 
degenerative disease. Therefore, approaches that have been developed to target Cripto-1 in 
cancer might benefit also different diseases.  
7. Conclusions 
Critical signaling pathways are involved in modulating embryonic stem cell fate and 
behavior, maintaining a delicate balance between survival and self-renewal signals. Among 
these ES cell “signature” pathways, Cripto-1 is a critical gene that is used by ES cells. For 
instance, Cripto-1 is either a downstream target of ES transcription factors and/or signaling 
pathways or can modulate other ES cell signaling cascades (Fig. 3). Further, deregulation of 
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stem cell self-renewal is probably a requirement for the initiation and formation of CSCs and 
therefore embryonic stem cell signature genes are also involved in cancer formation. Cripto-
1 is indeed an embryonic gene that is re-expressed in an aberrant spatial and temporal 
manner in a variety of human tumors. Recent evidence has clearly demonstrated that 
Cripto-1 is expressed by a subset of cancer cells with stem-like characteristics (Watanabe et 
al., 2010). CSCs are considered to be a major obstacle in the complete eradication of tumors 
due their innate resistance to conventional therapy and therefore identification of surface 
markers that might discriminate CSCs from the bulk population of tumor cells is under 
active investigation. Therefore, Cripto-1 targeting in human tumors might have a major 
breakthrough in cancer therapy. Several approaches have been used to target Cripto-1 in 
cancer cells in vitro and in vivo, from antisense oligonucleotides to blocking monoclonal 
antibodies (Bianco & Salomon, 2010). Translation of Cripto-1 research to a clinical setting 
has been recently achieved. In fact, a humanized anti-Cripto-1 antibody conjugated with a 
potent cytotoxin is currently being evaluated in a Phase I clinical study in cancer patients. In 
conclusion, a complete understanding of Cripto-1 signaling in stem cell biology offers a 
great promise for improving stem cell mediated regenerative therapy as well as cancer 
therapy.  
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